Over the course of the summer, there was a vital discovery that severe, late stage COVID-19 which had been considered a near fatal condition could be successfully treated with dexamethasone, a corticosteroid. One of the key clinicians behind that discovery was Dr Pierre Kory, the President of the Front-Line COVID-19 Critical Care Alliance (FLCCC). Today, corticosteroid is part of the standard COVID-19 pathway, in no small part due to the efforts of the FLCCC. Last month, Dr Kory again lit up the internet, giving a forceful testimony in front of the US Senate Homeland Security Committee, describing the “miraculous impact” of the antiparasitic agent ivermectin in the treatment and prevention of COVID-19. Could it be possible that Dr Kory and the team at the FLCCC have twice found successful treatments in the fight against COVID-19? Can lightning strike twice? In this podcast, we discuss the evidence behind the FLCCC’s use of ivermectin for both in the prevention and treatment of COVID-19. We outline why this team of internists at the FLCCC have succeeded in potentially finding two significant treatments for COVID-19 when the majority of the world’s public health establishment have been mired in indecision and a lack of innovation. Dr Kory discusses the challenges he’s met changing set opinions once many clinicians have put treatment paradigms into practice. He also touches upon the toxic environment that exists for those practitioners on the front lines trying to promote improved treatment protocols in an increasingly politicized medical landscape where prevailing opinions are often dictated by dogma, orthodoxy and bureaucracy, rather than by following the clear path created by evidence-based medicine. This podcast is made possible with the support of PharmaCCXSee omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related